Table 1.
Parameter and Group | Basal Period | Experimental Period
|
|||
---|---|---|---|---|---|
P1 | P2 | P3 | P4 | ||
Arterial blood 5-HT, mg/l | |||||
SAL | 0.9±0.2 | 0.8±0.2 | 0.8±0.2 | 0.8±0.2 | 0.7±0.2 |
HTP | 1.0±0.2 | 1.0±0.2 | 1.1±0.2 | 1.3±0.3 | 2.0±0.6* |
Net hepatic 5-HT balance, μg·kg−1·min−1 | |||||
SAL | 2.2±0.5 | 1.7±1.0 | 0.4±1.5 | −0.1±2.2 | 1.2±1.4 |
HTP | −2.8±2.9 | −3.3±1.9 | −4.0±1.8 | −2.8±3.1 | −7.4±3.4* |
Arterial plasma insulin, pmol/l | |||||
SAL | 46±8 | 108±18 | 110±11 | 129±13 | 135±17 |
HTP | 27±3 | 120±9 | 123±11 | 143±11 | 155±6 |
Hepatic sinusoidal insulin, pmol/l | |||||
SAL | 128±21 | 417±67 | 425±45 | 399±47 | 414±37 |
HTP | 181±15 | 411±34 | 359±39 | 383±44 | 386±40 |
Arterial plasma glucagon, ng/l | |||||
SAL | 46±7 | 41±5 | 38±5 | 38±4 | 35±8 |
HTP | 33±4 | 39±4 | 28±3 | 32±3 | 34±2 |
Hepatic sinusoidal glucagon, ng/l | |||||
SAL | 54±8 | 58±8 | 56±5 | 52±5 | 48±4 |
HTP | 45±7 | 44±4 | 42±4 | 47±4 | 42±5 |
Arterial plasma cortisol, nmol/l | |||||
SAL | 74±24 | 64±18 | 55±14 | 43±10 | 62±10 |
HTP | 82±21 | 66±12 | 51±12 | 72±33 | 116±43 |
Arterial plasma norepinephrine, pg/ml | |||||
SAL | 185±39 | 154±33 | 152±52 | 177±39 | 173±44 |
HTP | 114±38 | 139±59 | 115±57 | 140±65 | 142±49 |
Arterial plasma epinephrine, pg/ml | |||||
SAL | 149±55 | 78±33 | 55±14 | 74±33 | 75±39 |
HTP | 102±43 | 93±39 | 79±43 | 112±55 | 61±38 |
Values are means ± SE. 5-HT, 5-hydroxytryptamine. SAL dogs (n = 7) received intraportal saline infusion during periods 1–4 (P1–P4); HTP dogs (n = 6) received saline during P1 and intraportal 5-hydroxytryptophan (5-HTP) at 10, 20, and 40 μg·kg−1·min−1, respectively, during P2–P4. Negative values indicate net hepatic uptake.
P < 0.05 vs. SAL.